clinical trial · NCT04674761
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Albireo·phase3·completed·n = 52
Alagille SyndromeOdevixibatPlacebo
brief summary
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.
started
Mar 19, 2021
primary completion
Sep 9, 2022
completion
Sep 9, 2022
last updated
Nov 2, 2023
detailed description
Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
official title
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol